1 / 13

Janet Baker Haem-Onc Daycare/Apheresis

Thrombotic Thrombocytopenic Purpura(TTP) Post -AllogeneicTransplant A haematological emergency: a nursing challenge. Janet Baker Haem-Onc Daycare/Apheresis Royal Marsden NHS Trust 18/11/2011. Objectives. What is TTP?

kyle-freeman
Download Presentation

Janet Baker Haem-Onc Daycare/Apheresis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Thrombotic Thrombocytopenic Purpura(TTP) Post -AllogeneicTransplantA haematological emergency: a nursing challenge Janet Baker Haem-Onc Daycare/Apheresis Royal Marsden NHS Trust 18/11/2011

  2. Objectives What is TTP? Post-Transplant TTP Case Study Nursing Challenges Discussion points

  3. What is TTP? Systemic thrombotic disease Mostly affecting small blood vessels Characterised by: - thrombocytopenia - elevated LDH - decreased haemoglobin - > 4 % red cell fragments on blood film May be neurological/ renal symptoms and fever

  4. What causes TTP? Endothelial damage Platelet aggregation Red cell shearing and fragmentation Ischaemia to microvasculature,brain/lungs/kidneys-causing symptoms and potential organ failure TTP - spectrum of diseases? Congenital or acquired(post-pregnancy/viral) Auto-antibodies against ADAMTS 13

  5. ADAMTS 13 A protein that regulates von Willebrand Factor(vWF) vWF circulates in plasma as large units(multimers) Helps platelets to adhere to vascular surfaces ADAMTS 13 breaks down large units Without it - excessive platelet aggregation Classic TTP -caused by deficiency of ADAMTS 13 Deficiency caused by auto-antibody (IgG) Blood test can detect antibody

  6. Post-Transplant TTP ADAMTS 13 - no role Post-transplant MAHA (microangiopathic haemolytic anaemia) TAM (transplant associated microangiopathy) Endothelial damage caused by conditioning regimen(chemo/TBI)and/or Cyclosporin ? Other factors/GVHD Rare < 5% of all transplants …….but huge challenge Role of Therapeutic Plasma Exchange

  7. Case Study Mary-21 year old female Natural Killer cell leukaemia Full Intensity MUD Cyclophosphamide/TBI/Alemtuzumab with Cyclosporine (CSA) Discharged Day + 18 - good engraftment (platelets 242) Day + 27 - post-transplant clinic Rash,forgetful,fever,poor oral intake Creatinine 240 LDH 750 Platelets 32 Admitted:CSA stopped / MMF started Seizures,renal and respiratory impairment Red cell fragments on blood film Transferred to Critical Care Unit Working diagnosis: TTP Day + 30 - daily Therapeutic Plasma Exchange (TPE)

  8. Mary’s Story cont. Day 7 of TPE:Plts 13 LDH 700 : Refractory disease Other medications used: - steroids - Defibrotide - Vincristine x 2 - Cyclophosphamide x 1 - Rituximab x 4 Transferred from CCU to Transplant Unit Day + 52 Died Day + 78 : renal failure secondary to TTP

  9. Mary’s Story cont. Mary had a total of 37 TPE procedures Blood counts day of death: - Platelets 11 (lowest 10) - Hgb 7.2 (lowest 6.9) - Wbc 0.3 - LDH 428 (highest 1395) Normal=98- 192

  10. Points for Discussion Apheresis nurses:Role of TPE as first line therapy ? Evidence-base ASFA/BSCH guidelines Decision-making re:termination of TPE Patient/Family Advocate TPE: which Replacement Solution? Nursing Challenges

  11. Plasma Replacement in TTP

  12. References Journal of Clinical Apheresis:Clinical Applications of Therapeutic Apheresis,an evidence based approach.Volume 25.Issue 3 2010 http://www.transfusion guidelines.org.uk www.bcshguidelines.com Marr H,et al.Successful treatment of transplant-associated microangiopathy with rituximab.New Zealand Medical Journal.2009.122:1292

  13. Questions?

More Related